STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

KRYS KRYSTAL BIOTECH INCORPORATED StockScouter® Report

7

StockScouter® Score

KRYSTAL BIOTECH INCORPORATED, a mid cap company in the healthcare sector, is expected to slightly outperform the market over the next six months with slightly less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The multi-period measure of relative price change and consistency is well above average. Positive
  • One or more analysts has significantly increased quarterly earnings estimates for KRYS. Positive

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • Two or more executives, board directors or major shareholders – including one high-level executive -- sold a large number of shares recently. Very negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be out of favor, stocks will be , and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 40% done.
Progress: 80% done.
Low
High

Core Model Grades

C
F
N/A
A

Previous Ratings

9
6
5